Author:
Aytac U,Sato K,Yamochi T,Yamochi T,Ohnuma K,Mills G B,Morimoto C,Dang N H
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Aytac U, Claret F-X, Ho L, Sato K, Ohnuma K, Mills GB, Cabanillas F, Morimoto C, Dang NH (2001) Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G2/M checkpoint. Cancer Res 61: 7204–7210
2. Bauvois B, De Meester I, Dumont J, Rouillard D, Zhao HX, Bosmans E (1999) Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. Br J Cancer 79: 1042–1048
3. Beck WT, Danks MK, Wolverton JS, Kim R, Chen M (1993) Drug resistance associated with altered DNA topoisomerase II. Adv Enzyme Regul 33: 113–127
4. Burden DA, Osheroff N (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1400: 139–154
5. Carbone A, Gloghini A, Zagonel V, Aldinucci D, Gattei V, Degan M, Improta S, Sorio R, Monfardini S, Pinto A (1995) The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood 86: 4617–4626
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献